Investors

Press Releases

Date Title View
Toggle Summary Tetraphase Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
WATERTOWN, Mass. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports Third Quarter 2016 Financial Results and Reviews Recent Progress
WATERTOWN, Mass. , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the third quarter ended
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces Eight Data Presentations at IDWeek 2016
WATERTOWN, Mass. , Oct. 26, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced eight data presentations at IDWeek 2016, taking place October 26-30 in New Orleans , LA.  Presentations will include information about the company's phase 3 antibiotic candidate,
View HTML
Toggle Summary Tetraphase Pharmaceuticals Doses First Patient in IGNITE4 Phase 3 Clinical Trial of Eravacycline in cIAI
Top-line IGNITE4 Data Expected in 4Q 2017 Results to Support NDA Filing for IV Eravacycline in cIAI WATERTOWN, Mass. , Oct. 14, 2016 (GLOBE NEWSWIRE) --   Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced dosing of the first patient in IGNITE4, the Company's phase 3 clinical trial
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at 2016 Wedbush PacGrow Healthcare Conference
WATERTOWN, Mass. , Aug. 08, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
WATERTOWN, Mass. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the second quarter ended
View HTML
Toggle Summary Tetraphase Pharmaceuticals Initiates Phase 1 Clinical Trial for TP-6076, a Second-Generation Antibiotic Candidate Highly Active Against MDR Bacteria
WATERTOWN, Mass. , Aug. 01, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the initiation of patient dosing in a phase 1 clinical trial for intravenous (IV) TP-6076, a novel antibiotic candidate being developed for the treatment of serious and
View HTML
Toggle Summary Tetraphase Pharmaceuticals Added to the Russell Microcap® Index
WATERTOWN, Mass. , June 28, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that it was added to the Russell
View HTML
Toggle Summary Tetraphase Pharmaceuticals Presents Antibiotics Pipeline Data at ASM Microbe 2016
Includes Phase 3 Clinical Trial Data from IGNITE1 and IGNITE2
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at 2016 JMP Securities Life Sciences Conference
WATERTOWN, Mass. , June 15, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML